MedTrace Logo

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

NCT00447694 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-06-14

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to evaluate changes in cardiac iron as measured by MRI T2\* in beta-thalassemia patients with deferasirox treatment.

Conditions

Interventions

DRUG

Deferasirox

Oral deferasirox 30mg/kg/day once per day for 77 weeks.

Sponsors & Collaborators

Principal Investigators

  • Thomas Coates, MD · Childresn's Hospital of Los Angeles

  • Alexis Thompson, MD · Children's Memorial Hospital of Chicago

  • Paul Harmatz, MD · Children's Hospital and Research Center at Oakland

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00447694 on ClinicalTrials.gov